Options Trading News

April 18, 2013  Thu 7:32 AM CT

Respiratory Drug Closer to Approval

Theravance announced that a Food & Drug Administration panel voted in favor of approving its BREO Ellipta respiratory drug. THRX is up 15 percent before the bell on my tradeMONSTER platform.

Select Comfort Earnings, Revenue Miss

Select Comfort reported first-quarter earnings of $0.41 a share, missing the $0.43 average analyst estimate. Revenue of $258.2 million also missed the $288 million consensus number, and management cut full-year profit guidance. SCSS drops 3 percent in early trading.

Weak Sales Hurt eBay

EBay's earnings beat by a penny, but revenue was just $3.75 billion. Analysts had forecast $3.77 billion. Guidance was also lower than expected, and EBAY is down 3.5 percent in the premarket.
Share this article with your friends


Premium Services

Archived Webinar

Education & Strategy

Options Academy: More on the Covered Call Strategy

Last week, we talked about the Covered Call and the misconceptions that surround it. We spoke about how an investor must realize that the Covered Call is actually a premium collection strategy and not so much a directional one. If an investor can grasp this idea, the investor stands to do a heck of a lot better in the strategy than they currently do.

View more education articles »